The Mount Sinai Health System is at the forefront of skin cancer research, conducting both clinical trials and basic science studies to advance our understanding of skin cancers and to develop new treatments. With a prominent team of basic scientists and translational researchers recruited from leading institutions, our goal is to move beyond the limitations of standard therapy.
In the area of melanoma, for example, our researchers are working to identify therapies for stage IV disease that provide durable benefit in a very high percentage of people. For early stage melanomas, we are developing tests to predict the likelihood of recurrence and investigating treatment approaches to decrease the chances that a melanoma will come back. We work with immunologists, molecular biologists, cell biologists, and geneticists to make novel discoveries.
Mount Sinai has a robust clinical trials program for skin cancer. We are actively enrolling patients in a number of current studies, including the following:
- A Multi-center, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine: A study to confirm the safety of the investigational vaccine POL-103A and test if its administration on a regular schedule can increase the immune system activity, which is thought to delay the melanoma from coming back.
- Establishing A Gene Signature for Early-Stage Melanoma at High Risk of Reoccurrence: In this study we have three aims: screen the dermatopathology database at Mount Sinai and identify melanoma specimens from patients who have recurrent versus non recurrent melanoma; establish a protocol for extraction of RNA from paraffin embedded primary melanoma tissues; and establish an inflammatory signature for early stage melanoma. (This is a non-treatment trial.)